A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure

Trial Profile

A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mast Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Oct 2016 Status changed from recruiting to discontinued for administrative reasons not related to safety or efficacy.
    • 20 Sep 2016 According to Mast Therapeutics media release, company plans to perform an interim analysis of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top